Interpretation of 2021 French Guidelines for the Therapeutic Management of Bullous Pemphigoid.
10.3881/j.issn.1000-503X.14912
- Author:
Si-Hang WANG
1
;
Ya-Gang ZUO
1
Author Information
1. State Key Laboratory of Complex Severe and Rare Diseases,National Clinical Research Center for Dermatologic and Immunologic Diseases,Department of Dermatology,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
- Publication Type:Journal Article
- Keywords:
bullous;
guidelines;
pemphigoid;
therapy
- MeSH:
Humans;
Pemphigoid, Bullous/drug therapy*;
Autoimmune Diseases/drug therapy*;
Glucocorticoids/therapeutic use*;
Adrenal Cortex Hormones/therapeutic use*
- From:
Acta Academiae Medicinae Sinicae
2022;44(5):828-836
- CountryChina
- Language:Chinese
-
Abstract:
Bullous pemphigoid (BP) is a common autoimmune subepidermal bullous disease.The diagnosis of BP relies on clinical manifestation,histopathology,direct and indirect immunofluorescence,and serological assay.In the past two decades,topical corticosteroids and systemic and/or topical corticosteroids were the major therapeutic options for localized/mild/moderate and extensive/severe BP,respectively.In 2021,several experts from the French Study Group on Autoimmune Bullous Skin Diseases collaboratively issued the updated guidelines for the therapeutic management of BP based on evidence-based medicine.The guidelines fully detailed the updated therapeutic options for extensive BP,BP of limited extent,localized form of BP,corticosteroid-dependent BP,and drug-induced/associated BP.In particular,systemic corticosteroids are no longer the first-line treatment for extensive BP.We interpret the guidelines to assist dermatologists in the comprehensive management of BP and promote the standardization of BP treatment.
